This narrative review examines how biological markers might predict the effectiveness of allergen-specific immunotherapy for allergic diseases. The authors look at combining immunoglobulins, such as sIgE and tIgE, along with their ratios and cytokine levels like IL-10 and IL-35. They suggest these markers could help build a composite prediction scoring system to improve accuracy in forecasting clinical outcomes.
The review also highlights the importance of monitoring changes in specific markers over time. Tracking sIgE, sIgG4, sIgG2, cellular markers, and cellular functions can help assess patient adherence and guide therapy decisions. These biological measures are closely associated with clinical results during long-term treatment.
The study notes a key limitation: a standardized, unified panel of biological parameters has not yet been established. Because this review is narrative and does not report specific adverse events or discontinuations, readers should view these findings as a framework for future research rather than immediate clinical proof. Combining these markers may eventually improve how doctors tailor treatment for allergic conditions.